BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 11294418)

  • 1. The co-expression of p53 protein and P-glycoprotein is correlated to a poor prognosis in osteosarcoma.
    Park YB; Kim HS; Oh JH; Lee SH
    Int Orthop; 2001; 24(6):307-10. PubMed ID: 11294418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 and P-glycoprotein are often co-expressed and are associated with poor prognosis in breast cancer.
    Linn SC; Honkoop AH; Hoekman K; van der Valk P; Pinedo HM; Giaccone G
    Br J Cancer; 1996 Jul; 74(1):63-8. PubMed ID: 8679460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P-glycoprotein and metallothionein expression and resistance to chemotherapy in osteosarcoma.
    Shnyder SD; Hayes AJ; Pringle J; Archer CW
    Br J Cancer; 1998 Sep; 78(6):757-9. PubMed ID: 9743295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of P-glycoprotein and p53 in advanced hepatocellular carcinoma treated by single agent chemotherapy: clinical correlation.
    Chou YY; Cheng AL; Hsu HC
    J Gastroenterol Hepatol; 1997 Aug; 12(8):569-75. PubMed ID: 9304508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between P-glycoprotein expression and p53 status in high-grade osteosarcoma.
    Serra M; Maurici D; Scotlandi K; Barbanti-Brodano G; Manara MC; Benini S; Picci P; Bertoni F; Bacci G; Sottili S; Baldini N
    Int J Oncol; 1999 Feb; 14(2):301-7. PubMed ID: 9917506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meta-analysis of clinical significance of p53 protein expression in patients with osteosarcoma.
    Wu J; Guo A; Li Q; Wang D
    Future Oncol; 2017 Sep; 13(21):1883-1891. PubMed ID: 28766969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of HER2/erbB-2 correlates with survival in osteosarcoma.
    Gorlick R; Huvos AG; Heller G; Aledo A; Beardsley GP; Healey JH; Meyers PA
    J Clin Oncol; 1999 Sep; 17(9):2781-8. PubMed ID: 10561353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The effect of resistance-related proteins on the prognosis and survival of patients with osteosarcoma: an immunohistochemical analysis].
    Ozger H; Eralp L; Atalar AC; Toker B; Esberk Ateş L; Sungur M; Bilgiç B; Ayan I
    Acta Orthop Traumatol Turc; 2009; 43(1):28-34. PubMed ID: 19293613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of molecular markers in the tumor and survival prognosis in osteosarcoma.
    Boulytcheva IV; Soloviev YN; Kushlinskii NE; Mahson AN
    Bull Exp Biol Med; 2010 Dec; 150(2):237-42. PubMed ID: 21240382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stage-IIB osteosarcomas around the knee. A study of MMP-9 in surviving tumour cells.
    Foukas AF; Deshmukh NS; Grimer RJ; Mangham DC; Mangos EG; Taylor S
    J Bone Joint Surg Br; 2002 Jul; 84(5):706-11. PubMed ID: 12188489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High expression of MDR-1 gene and P-glycoprotein in initial and re-biopsy specimens of relapsed B-cell lymphoma.
    Liu Q; Ohshima K; Kikuchi M
    Histopathology; 2001 Mar; 38(3):209-16. PubMed ID: 11260300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of tumor suppressors in osteosarcoma before and after neoadjuvant chemotherapy.
    Robl B; Pauli C; Botter SM; Bode-Lesniewska B; Fuchs B
    BMC Cancer; 2015 May; 15():379. PubMed ID: 25956431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of P-glycoprotein, HER-2/ErbB-2, p53, and Bcl-2 in primary tumor and metachronous lung metastases in patients with high-grade osteosarcoma.
    Ferrari S; Bertoni F; Zanella L; Setola E; Bacchini P; Alberghini M; Versari M; Bacci G
    Cancer; 2004 May; 100(9):1936-42. PubMed ID: 15112275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expressions of p53, c-MYC, BCL-2 and apoptotic index in human osteosarcoma and their correlations with prognosis of patients.
    Wu X; Cai ZD; Lou LM; Zhu YB
    Cancer Epidemiol; 2012 Apr; 36(2):212-6. PubMed ID: 21890444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of P-glycoprotein (Pgp) expression in human osteosarcoma by high-throughput tissue microarray.
    Gao Y; Liao Y; Shen JK; Feng Y; Choy E; Cote G; Harmon D; Mankin HJ; Hornicek FJ; Duan Z
    J Orthop Res; 2016 Sep; 34(9):1606-12. PubMed ID: 26790551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. P-glycoprotein expression: critical determinant in the response to osteosarcoma chemotherapy.
    Chan HS; Grogan TM; Haddad G; DeBoer G; Ling V
    J Natl Cancer Inst; 1997 Nov; 89(22):1706-15. PubMed ID: 9390540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 99mTc-MIBI imaging as a predictor of therapy response in osteosarcoma compared with multidrug resistance-associated protein and P-glycoprotein expression.
    Burak Z; Moretti JL; Ersoy O; Sanli U; Kantar M; Tamgac F; Basdemir G
    J Nucl Med; 2003 Sep; 44(9):1394-401. PubMed ID: 12960182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteins expressed in osteosarcoma and serum levels as prognostic factors.
    Trieb K; Kotz R
    Int J Biochem Cell Biol; 2001 Jan; 33(1):11-7. PubMed ID: 11167128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High functional P-glycoprotein activity is more often present in T-cell acute lymphoblastic leukaemic cells in adults than in children.
    Plasschaert SL; Vellenga E; de Bont ES; van der Kolk DM; Veerman AJ; Sluiter WJ; Daenen SM; de Vries EG; Kamps WA
    Leuk Lymphoma; 2003 Jan; 44(1):85-95. PubMed ID: 12691146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of mutant P53 protein in osteosarcomas and other malignant and benign lesions of bone.
    Ueda Y; Dockhorn-Dworniczak B; Blasius S; Mellin W; Wuisman P; Böcker W; Roessner A
    J Cancer Res Clin Oncol; 1993; 119(3):172-8. PubMed ID: 8418091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.